Epitope Specific T-Cell Immunity to Breast Cancer.
Abstract
We analyzed the ability of T cells from PBMC of breast cancer patients to recognize HBR-2/neu (HER-2) peptides. We found that 13/18 patients responded by proliferation to at least one of the HER-2 peptides tested. Of these peptides, one designated G89 (HER-2:777-789) was recognized by T cells from 10 patients. 7/9 responding patients were HLA- DR4+, suggesting that this peptide is recognized preferentially in association with HLA-DR4. Analysis of the specificity and restriction of the cytokine responses by G89-stimulated T cells revealed that these cells secreted significantly higher levels of IFN-gamma than lL-4 and IL-lO suggesting priming for a T helper 1 (Thl) response. The same pattern of responses was observed to the intracellular domain (ICD) of HER-2 suggesting that G89-stimulated T cells recognized epitopes of the HER-2 protein in association with HLA-DR4. Since HLA-DR4 is present in 25% of the humans, characterization of MHC-class II restricted epitopes inducing Thl responses may provide a basis for the development of multivalent HER-2 based vaccines against breast and ovarian cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1998
- Accession Number
- ADA363609
Entities
People
- Constantin G. Ioannides
Organizations
- The University of Texas MD Anderson Cancer Center